Somatropin Side Effects: What Studies Report

Evidence tier: Established. Somatropin is the international nonproprietary name (INN) for recombinant human growth hormone manufactured for therapeutic use. It is a prescription biologic approved in the United States, the European Union and many other jurisdictions for defined indications, and it has been studied in randomised controlled trials, multi-year post-marketing registries and pharmacovigilance databases for several decades. The adverse-event literature is therefore comparatively mature: the questions researchers have asked are less about whether effects exist and more about their frequency, reversibility and how they differ across patient populations and product formats.

Brand names appearing in the cited literature are used descriptively for identification only; each such name is a trademark of its owner, and PeptideU is not affiliated with or endorsed by any manufacturer, marketing authorisation holder or study sponsor. This page for educational purposes summarises published findings and does not describe how any product is prepared, administered or dosed.

What the Evidence Base Looks Like

Three broad sources inform what is known about somatropin tolerability. The first is randomised trials, typically designed to test a newer long-acting growth hormone analogue against daily somatropin as an active comparator; in those designs somatropin functions as the reference arm, so its adverse-event profile is captured alongside the investigational product. The second is observational registries that followed large paediatric cohorts across many indications for years. The third is spontaneous reporting and pharmacovigilance analysis, which detects rare or unexpected signals but cannot establish incidence or causation.

Each source has a different weakness. Trials are short and enrol selected participants. Registries are large but rely on clinician reporting and lack randomised controls. Pharmacovigilance databases capture rare events but are subject to reporting bias and under-reporting, a limitation researchers examined directly in an analysis of biologic pharmacovigilance in a multisource environment, which reported that when several manufacturers supply the same biologic molecule, attributing an adverse event to a specific product requires precise naming and traceability (PMID 29172979).

Injection-Site and Local Reactions: What Studies Report

Local reactions are among the most frequently tabulated events in growth hormone trials. In a phase 3 study comparing weekly somatrogon with daily somatropin in children with growth hormone deficiency, the study reported injection-site pain among the adverse events recorded in both arms, with a higher frequency in the weekly somatrogon group than in the daily somatropin group (PMID 35405011). In the phase 3 heiGHt trial of weekly lonapegsomatropin in treatment-naïve children with growth hormone deficiency, researchers reported that the overall adverse-event profile was similar between the weekly product and the daily somatropin comparator (PMID 34272849).

These comparisons matter because they separate effects attributable to the hormone from effects attributable to the delivery format. An updated Growth Hormone Research Society consensus statement on long-acting growth hormone discussed how tolerability, monitoring and long-term safety surveillance should be framed when weekly formulations are compared with daily somatropin (PMID 42676236).

Fluid Retention and Musculoskeletal Complaints: What Studies Report

Growth hormone influences sodium and water handling, and the clinical literature has long tabulated oedema, arthralgia, myalgia and carpal-tunnel-type symptoms as class-associated events, most prominently in adults. Reviews of mammalian cell-derived somatropin in HIV-associated wasting reported that treatment-emergent adverse events were commonly musculoskeletal in nature and generally mild to moderate in the trials summarised (PMID 16526830), and a companion spotlight review of the same indication described a comparable tolerability picture (PMID 16724867).

In adults with growth hormone deficiency, the foresiGHt trial of once-weekly lonapegsomatropin evaluated efficacy and safety against comparator arms and reported the adverse events observed over the randomised treatment period (PMID 41420532). Adult and paediatric profiles are not interchangeable in the published record: fluid-retention and joint complaints appear more prominently in adult datasets, while paediatric datasets emphasise growth-related and skeletal observations.

Glucose-Related Measures: What Studies Report

Because growth hormone opposes some actions of insulin, glucose handling is a standing monitoring item in trials. Reviews of somatropin in HIV-associated wasting reported effects on glucose tolerance among the adverse events considered clinically relevant in that population (PMID 16526830). In paediatric research, the full KIGS cohort analysis examined safety across indications in a large international registry of children treated with growth hormone and reported on the adverse events captured during surveillance, including metabolic outcomes (PMID 36102184). The published emphasis is on laboratory monitoring rather than on any assumption that changes are uniform or permanent.

Paediatric Registry and Population-Specific Findings

Large multi-indication registries

The KIGS analysis is the largest single source cited on this page: researchers assembled long-term data from children treated with growth hormone across multiple diagnoses and reported both effectiveness outcomes and the safety events recorded over the registry's lifetime, with serious adverse events described as uncommon relative to the size of the cohort (PMID 36102184).

Prader–Willi syndrome

Prader–Willi syndrome is studied separately because respiratory, sleep and skeletal considerations differ from those in isolated growth hormone deficiency. The PATRO Children study reported safety and effectiveness data for growth hormone treatment in children with Prader–Willi syndrome, and the study characterised the adverse events observed during observational follow-up (PMID 39371577).

Idiopathic short stature versus growth hormone deficiency

Indication also shapes the risk–benefit discussion. A comparative analysis of growth hormone treatment outcomes in paediatric idiopathic short stature and growth hormone deficiency reported differences between the two groups in treatment response, underlining that safety findings from one diagnostic group are not automatically transferable to another (PMID 40980545).

Rare Signals and Pharmacovigilance Methods

Rare events are handled by disproportionality analysis of spontaneous reporting databases rather than by trials. A real-world pharmacovigilance analysis of medication-associated memory disorder applied that approach to a large spontaneous reporting database and reported the drug classes for which memory-disorder reports were disproportionately represented (PMID 40816367). Analyses of this design describe reporting patterns, not incidence, and the authors of the biologics pharmacovigilance review emphasised that signal interpretation depends on accurate product identification when multiple sources of the same molecule are marketed (PMID 29172979).

Product Authenticity as a Safety Variable

A distinct strand of the literature concerns products that are not pharmaceutical-grade at all. Researchers who obtained purported somatropin products offered over the internet reported on their availability and analysed their quality, documenting deficiencies among the illegitimate products examined (PMID 27888454). That finding is frequently cited to make the point that adverse effects observed outside regulated supply chains cannot be attributed to the approved biologic, because content, identity and sterility were not verified.

Reported Event Categories at a Glance

How to Read This Literature Critically

• Comparator arms are informative. When daily somatropin serves as the control, as in the heiGHt trial where researchers reported comparable overall adverse-event profiles between arms, both products' event tables are generated under the same protocol (PMID 34272849).
• Registry size is not the same as randomisation. The KIGS cohort analysis reported long-term surveillance data without a randomised control group (PMID 36102184).
• Indication changes the question. The comparative analysis of idiopathic short stature and growth hormone deficiency reported differing outcomes between diagnoses (PMID 40980545).
• Consensus documents synthesise, they do not generate data. The Growth Hormone Research Society statement on long-acting growth hormone discussed monitoring and surveillance expectations rather than reporting new trial results (PMID 42676236).
• Disproportionality is not incidence. The real-world memory-disorder pharmacovigilance analysis reported reporting patterns within a spontaneous database (PMID 40816367).

What the Cited Literature Does Not Establish

The verified papers summarised here do not provide individualised risk estimates, do not compare somatropin products against one another for rare outcomes, and do not support extrapolation from one indication to another. Several are formulation-comparison trials whose primary endpoints were growth or body-composition outcomes rather than safety, so their event tables are secondary observations. Trial duration also limits inference: short randomised periods cannot characterise events with long latency, which is precisely why registry and pharmacovigilance approaches exist alongside them, as researchers noted when discussing traceability for biologics (PMID 29172979).

This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified healthcare professional for any question about a prescription medicine, monitoring, or a reported adverse event. Somatropin is a prescription biologic, and decisions about its clinical use, suitability and surveillance sit with treating clinicians and regulators, not with an educational summary. Readers seeking background on what growth hormone is, how it has been studied and how the formulation landscape evolved can work through the somatropin course linked in the related material; this page is limited to what the safety and adverse-event literature reports.

References

• Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort (The Journal of Clinical Endocrinology and Metabolism, 2022)
• Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial (The Journal of Clinical Endocrinology and Metabolism, 2021)
• Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis (Journal of Affective Disorders, 2025)
• Pharmacovigilance of Biologics in a Multisource Environment (Journal of Managed Care & Specialty Pharmacy, 2017)
• Growth hormone treatment in children with Prader-Willi syndrome: safety and effectiveness data from the PATRO Children study (Therapeutic Advances in Endocrinology and Metabolism, 2024)
• Spotlight on mammalian cell-derived somatropin in HIV-associated wasting (BioDrugs, 2006)
• Mammalian cell-derived somatropin: a review of its use in the management of HIV-associated wasting (Drugs, 2006)
• Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency (Journal of the Endocrine Society, 2025)
• Availability and quality of illegitimate somatropin products obtained from the Internet (International Journal of Clinical Pharmacy, 2017)
• Long-acting growth hormone: An updated Growth Hormone Research Society consensus statement (European Journal of Endocrinology, 2026)
• Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial Results (The Journal of Clinical Endocrinology and Metabolism, 2026)